Q-omics provides the consensus-scored KRT8P39 profile across patient tissues and cancer cell-line models. KRT8P39 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KRT8P39 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, KRT8P39 RNA expression shows 17,886 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight ACC, KIRC, and DLBC as cancer lineages where KRT8P39 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT8P39 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT8P39 survival associations across molecular data types. KRT8P39 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT8P39 RNA expression–survival associations across cancer types. High KRT8P39 expression shows unfavorable associations in ACC, LUAD, MESO, LGG and BLCA, but favorable associations in SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KRT8P39 RNA expression.
This table summarizes KRT8P39 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KRT8P39. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT8P39 shows higher tumor expression in KIRC, BLCA, HNSC, LUAD, STAD and UCEC. The KIRC box plot shows higher KRT8P39 RNA expression in tumor versus normal tissue (log2 FC = +0.244, t-test p < 0.001).
This table shows molecular features associated with KRT8P39 in patient tissues and cancer cell lines. In patient samples, KRT8P39 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
